NASDAQ · IMMX
Immix Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMMX: Nov 6, 2026
Immix Biopharma, Inc. Common Stock is estimated to report earnings on 11/06/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.24.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.18 | $-0.17 | $-0.20 | 3 |
| Dec 2026 | $-0.22 | $-0.19 | $-0.26 | 2 |
| Mar 2027 | $-0.22 | $-0.21 | $-0.23 | 2 |
| Jun 2027 | $-0.27 | $-0.26 | $-0.27 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · RTTNews · Fintel- Zacks · Oct 27, 11:56 AM EDTCan Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Can THC deliver a Q3 earnings beat? Ambulatory Care growth and higher revenues per adjusted admission offer support, but hospital volume declines and costs loom.
- MarketBeat · Oct 4, 11:02 PM EDTImmix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis StudyImmix Biopharma (NASDAQ:IMMX) reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis, and outlined plans for a biologics license application, a frontline study and a targeted commercial launch str
- RTTNews · Oct 2, 12:13 PM EDTWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) – The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic deals and corporate activity. Key updates spanned oncology, rare diseases, cardiov
- Fintel · Oct 2, 7:46 AM EDTImmix Biopharma Consensus Price Target Increased by 10.16% to $25.04The average one-year price target for Immix Biopharma (NASDAQCM:IMMX) has been revised to $25.04 / share. This is an increase of 10.16% from the prior estimate of $22.73 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not cons
- RTTNews · Sep 29, 9:48 AM EDTImmixBio Reports 89% CR Rate, Potential 98% With NXC-201 In AL Amyloidosis(RTTNews) – Immix Biopharma (IMMX), on Tuesday reported that an interim update from the Phase 2 NEXICART-2 study showed an 89% complete response (CR) rate with investigational NXC-201 in patients with relapsed/refractory AL amyloidosis.
- RTTNews · Sep 29, 9:40 AM EDTImmix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis(RTTNews) – Tuesday, Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis.
- Zacks · Jun 24, 12:00 PM EDTAll You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to BuyImmix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · Jun 18, 9:55 AM EDTWall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a BetThe consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · May 27, 9:55 AM EDTWall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · May 21, 8:21 AM EDTImmix Biopharma Prices $150 Million Underwritten Offering To Advance NXC-201 Program(RTTNews) – Immix Biopharma, Inc. (IMMX) announced that it has priced a $150 million underwritten registered offering of its common stock.
- RTTNews · May 21, 7:14 AM EDTImmix Biopharma Soars On 95% Complete Response Rate In Interim Data From NEXICART-2 Trial Of NXC-201(RTTNews) – Immix Biopharma, Inc. (IMMX) announced that it has achieved a complete response rate CR of 95% in the interim data of the NEXICART-2 trial evaluating NXC-201 in the treatment of relapsed/refractory AL Amyloidosis.
- Fintel · Apr 9, 8:35 AM EDTImmix Biopharma (IMMX) Price Target Increased by 11.73% to 18.62The average one-year price target for Immix Biopharma (NasdaqCM:IMMX) has been revised to $18.62 / share. This is an increase of 11.73% from the prior estimate of $16.66 dated March 25, 2026. The price target is an average of many targets provided by analysts.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Immix Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.